Qiagen N.V. Share Price Deutsche Boerse AG

Equities

QIA

NL0015001WM6

Biotechnology & Medical Research

Market Closed - Deutsche Boerse AG 09:17:41 24/05/2024 BST 5-day change 1st Jan Change
40.23 EUR +0.05% Intraday chart for Qiagen N.V. -4.21% -0.73%

Financials

Sales 2024 * 2.01B 1.85B 158B Sales 2025 * 2.14B 1.97B 168B Capitalization 9.7B 8.95B 762B
Net income 2024 * 407M 375M 31.96B Net income 2025 * 450M 415M 35.33B EV / Sales 2024 * 4.96 x
Net Debt 2024 * 251M 231M 19.67B Net cash position 2025 * 257M 237M 20.22B EV / Sales 2025 * 4.42 x
P/E ratio 2024 *
23.6 x
P/E ratio 2025 *
21.3 x
Employees 5,900
Yield 2024 *
-
Yield 2025 *
-
Free-Float 96.86%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.05%
1 week-4.21%
Current month+4.01%
1 month+4.41%
3 months+0.24%
6 months+4.73%
Current year-0.73%
More quotes
1 week
39.71
Extreme 39.705
42.08
1 month
38.10
Extreme 38.095
42.29
Current year
36.50
Extreme 36.5
43.01
1 year
34.00
Extreme 34
44.69
3 years
34.00
Extreme 34
53.05
5 years
23.38
Extreme 23.3814
53.05
10 years
17.24
Extreme 17.2363
78.58
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 31/01/15
Founder 69 28/04/96
Director of Finance/CFO 56 31/12/98
Members of the board TitleAgeSince
Director/Board Member 74 31/05/11
Founder 69 28/04/96
Chairman 66 25/06/13
More insiders
Date Price Change Volume
24/05/24 40.23 +0.05% 500
23/05/24 40.21 -0.37% 160
22/05/24 40.36 -2.86% 997
21/05/24 41.55 -1.26% 425
20/05/24 42.08 +0.19% 90

Delayed Quote Deutsche Boerse AG, May 24, 2024 at 09:17 am

More quotes
Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
43.73 USD
Average target price
50.14 USD
Spread / Average Target
+14.66%
Consensus